Publications by authors named "D Scuteri"

Background: According to scientific literature, some 99% of patients affected by Alzheimer's disease (AD) suffer from behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPSs). In particular, agitation is one of the most difficult disorders to treat. States of agitation represent a very serious problem as they make these subjects dangerous for themselves and others and worsen as the disease advances.

View Article and Find Full Text PDF
Article Synopsis
  • Approximately 57.4 million people worldwide are affected by dementia, with behavioral and psychological symptoms (BPSD), particularly agitation, being prevalent and often challenging to manage.
  • The BRAINAID trial tested a nanotechnology device, NanoBEO, on 29 elderly patients (65+) with severe dementia to evaluate its effectiveness in reducing agitation and pain, utilizing a randomized and placebo-controlled design.
  • Results indicated that NanoBEO significantly reduced agitation levels and frequency by 28% after 4 weeks, and showed notable pain relief (45.46% improvement) after just 1 week, without requiring additional medications.
View Article and Find Full Text PDF

The global impact of dementia is an increasing area of concern and, according to the Alzheimer's Disease International (ADI) World Alzheimer Report 2021, up to 90% of dementia patients in low- and middle-income countries are not diagnosed [...

View Article and Find Full Text PDF

A complication of diabetes is neuropathic pain, which is difficult to control with medication. We have confirmed that neuropathic pain due to mechanical allodynia in diabetic mice is mediated by a characteristic neuropeptide in the spinal cord. We evaluated the strength of mechanical allodynia in mice using von Frey filaments.

View Article and Find Full Text PDF

Hericenone C is one of the most abundant secondary metabolites derived from Hericium erinaceus, under investigation for medicinal properties. Here, we report that Hericenone C inhibits the second phase of formalin-induced nociceptive behavior in mice. As the second phase is involved in inflammation, in a mechanistic analysis on cultured cells targeting NF-κB response element (NRE): luciferase (Luc)-expressing cells, lipopolysaccharide (LPS)-induced NRE::Luc luciferase activity was found to be significantly inhibited by Hericenone C.

View Article and Find Full Text PDF